Performance Characteristics of the Becton Dickinson ProbeTec System for Direct Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urine Specimens in Comparison With the Roche Cobas System

2000 ◽  
Vol 124 (11) ◽  
pp. 1649-1652 ◽  
Author(s):  
Edward L. Chan ◽  
Ken Brandt ◽  
Karen Olienus ◽  
Nick Antonishyn ◽  
Greg B. Horsman

Abstract Objective.—The Becton Dickinson BDProbeTec ET System is a new semiautomated system using strand displacement amplification technology that simultaneously amplifies and detects Chlamydia trachomatis and Neisseria gonorrhoeae DNA. The strand displacement amplification products are hybridized with a fluorescent detector probe and are captured by a chemiluminescent assay in a microwell format. An amplification control is also included to monitor assay inhibition. This study evaluated the performance of the BDProbTec ET system in detecting C trachomatis and N gonorrhoeae in male and female urine specimens, calculated its ability to process large volumes of specimens, and determined the inhibition rate. Materials and Methods.—Eight hundred twenty-five male and 399 female urine specimens were tested for both C trachomatis and N gonorrhoeae with the BDProbeTec ET system, and results were compared with those of the Roche Amplicor Cobas system. All urine specimens were processed on both assays on the same day they were received, according to the manufacturers' instructions. Discrepant results were resolved by in-house polymerase chain reaction assays. Internal or amplification controls were also used in each specimen assay to monitor inhibition. The throughput of the BDProbTec ET system was further tested with 150 urine specimens on an 8-hour shift for 2 days. Results.—The overall sensitivity, specificity, positive predicative value, and negative predicative value for for detection of chlamydia were 95.3%, 99.3%, 95.9%, and 99.2% for strand displacement amplification and 95.9%, 98.3%, 90.6%, and 99.3% for the Roche Amplicor system. For detection of gonorrhea, these values were 100%, 99.7%, 88.2%, and 100% and 96.7%, 98.9%, 69%, and 99.9%, respectively. The overall inhibition rates for both strand displacement amplification and Roche Amplicor were less than 3.5%. The BDProbTec ET system was able to produce 150 results each for chlamydia and gonorrhea and the internal control within the 8-hour shift. Conclusions.—The performance characteristics of the BDProbeTec ET assay are similar to those of the Roche Amplicor polymerase chain reaction for detection of chlamydia and gonorrhea in male and female urine specimens. The system was able to produce 300 results in an 8-hour shift.

1996 ◽  
Vol 4 (5) ◽  
pp. 276-280
Author(s):  
R. Pasternack ◽  
A. Mustila ◽  
P. Vuorinen ◽  
P. K. Heinonen ◽  
A. Miettinen

Objective:The purpose of this study was to evaluate the benefits achievable by Amplicor polymerase chain reaction (PCR) (F. Hoffmann-LaRoche Ltd., Basel, Switzerland) with urine specimens in addition to PACE 2 (Gen-Probe, Inc., San Diego, California) assay with cervical swab specimens in the diagnosis ofChlamydia trachomatisin women.Methods:Cervical and urine specimens from 286 women were tested forC. trachomatisby PACE 2 and Amplicor PCR, respectively. All urine specimens were analyzed undiluted and diluted 1:10 to detect and eliminate possible PCR inhibition. A confirmatory PCR assay using major outer membrane protein-based primers (MOMP-PCR) was used on urine specimens that were positive by PCR from women who were negative by PACE 2 with cervical swab specimens.Results:Of the endocervical specimens, 26 were positive by the PACE 2 assay. The PCR with urine was positive in 21 of these patients. When the urine specimens were analyzed diluted 1:10, 4 of the 5 PCR-negative specimens from PACE 2-positive patients turned positive by the PCR. Additionally, 4 urine specimens from PACE 2-negative women were positive by the PCR with urine, and 3 of them could be confirmed by MOMP-PCR. Altogether, 29 women were found to be positive forC. trachomatisby either of the two assays.Conclusions:By using the PCR with urine specimens, an 11% increase in sensitivity could be achieved in addition to that obtained by PACE 2 assay with cervical swab specimens. In the present material, however, the increased sensitivity was reversed by the presence of PCR inhibitors in 14% of the female urine specimens. Amplicor PCR with urine specimens can undoubtedly be recommended for the diagnosis of chlamydial infections in women. However, constant monitoring of the PCR inhibition seems highly advisable to obtain full benefit of the sensitivity of the PCR.


2002 ◽  
Vol 13 (1_suppl) ◽  
pp. 19-22 ◽  
Author(s):  
Adriaan J C Van Den Brule ◽  
Christian Munk ◽  
Jeanette F Winther ◽  
Susanne Krüger Kjaer ◽  
Hans O Jørgensen ◽  
...  

Danish male military recruits (n = 388) were included in a follow-up study to investigate the prevalence and persistence of asymptomatic Chlamydia trachomatis infections. Urine specimens were collected at enrolment and after approximately six months. C. trachomatis was detected by polymerase chain reaction (Amplicor, Roche). Questionnaires were filled out concerning sexual behaviour and clinical symptoms. The prevalence of asymptomatic C. trachomatis in Danish male military recruits was 4.6% (18 out of 388). From five C. trachomatis-positive men no follow-up sample was obtained. From the remaining 13 C. trachomatis-positive men four (31%) were treated for C. trachomatis between the two visits (outside the study protocol). Of the remaining nine men, one cleared the infection and eight men (89%) had a persistent infection. The number of lifetime sexual partners was associated with the presence of C. trachomatis at enrolment. Although based on small numbers, this follow-up study shows, in contrast to women with asymptomatic C. trachomatis infections, a high percentage of C. trachomatis persistence in asymptomatically infected males.


Sign in / Sign up

Export Citation Format

Share Document